Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin
Iwan E Bennett, Kathryn M Field, Christopher M Hovens, Bradford A Moffat, Mark A Rosenthal, Katharine Drummond, Andrew H Kaye, Andrew P Morokoff
JOURNAL OF NEURO-ONCOLOGY | SPRINGER | Published : 2017
The CABARET trial was conducted by The Cooperative Trials Group for Neuro-Oncology (COGNO), and was funded in part by Roche. This analysis was supported in part by funding received from The Brain Foundation, the Neurosurgical Society of Australasia, the Cure for Life Foundation, and the Royal Australasian College of Surgeons.